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AbstrAct
Ewing sarcomas (ES) are pediatric bone tumors that arise from a driver 
translocation, most frequently EWS/FLI1. Current ES treatment involves DNA 
damaging agents, yet the basis for the sensitivity to these therapies remains unknown. 
Oncogene-induced replication stress (RS) is a known source of endogenous DNA 
damage in cancer, which is suppressed by ATR and CHK1 kinases. We here show that 
ES suffer from high endogenous levels of RS, rendering them particularly dependent 
on the ATR pathway. Accordingly, two independent ATR inhibitors show in vitro 
toxicity in ES cell lines as well as in vivo efficacy in ES xenografts as single agents. 
Expression of EWS/FLI1 or EWS/ERG oncogenic translocations sensitizes non-ES cells 
to ATR inhibitors. Our data shed light onto the sensitivity of ES to genotoxic agents, 
and identify ATR inhibitors as a potential therapy for Ewing Sarcomas.
INtrODUctION
Genomic instability is widespread in cancer cells, 
as already noticed in the Boveri studies of the early 20th 
century [1]. Hence, targeting genomic instability offers 
an opportunity to develop treatments that preferentially 
kill cancer cells. This idea gained momentum with the 
development of therapies such as inhibitors of poly (ADP-
ribose) polymerases (PARPs), which are highly toxic for 
cells with mutations in BRCA1/2 and thus defective in 
DNA repair by Homologous Recombination (HR) [2, 3]. 
An alternative to targeting a specific mutation is to exploit 
the presence of high endogenous levels of DNA damage 
in tumors. A well-established source of genomic instability 
in cancer is oncogene-induced RS [4]. As a consequence, 
targeting RS-response kinases ATR and CHK1 is 
preferentially toxic for tumors experiencing high levels of 
RS such as MYC-induced lymphomas, MLL-translocation 
driven leukemias or H-RAS driven fibrosarcomas [5-7]. 
In this context, the identification of cancers presenting 
high levels of RS is important to guide the use of ATR and 
CHK1 inhibitors in cancer therapy [8]. 
Several reasons led us to hypothesize that Ewing 
Sarcomas (ES) might be suffering from RS. First, the 
EWS/FLI1 translocation product is a bona fide oncogene 
due to its capacity to transform mouse fibroblasts [9] 
and, as mentioned, oncogenes are a known source of RS 
[4]. Second, current ES treatments use chemicals that 
perturb DNA replication such as the alkylating agent 
temozolomide or topoisomerase I inhibitors. Third, 
EWSR1 interacts with BARD1 which, together with 
BRCA1, regulates recombination processes that are 
essential for DNA replication [10]. Moreover, and similar 
to BRCA mutant tumors [2, 3], ES are also sensitive to 
PARP inhibitors [11, 12]. Finally, EWSR1-deficient mice 
present DNA damage, anemia and skeletal abnormalities 
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[13, 14]; which are also found in mice with reduced ATR 
levels that accumulate substantial amounts of RS [15]. For 
these reasons, we explored whether ES indeed suffer from 
high levels of RS and whether this would render them 
sensitive to ATR inhibition.
rEsULts
The presence of high levels of RS in cancer cells 
creates a pressure to acquire mutations that suppress RS 
and therefore facilitate their growth [16-18]. Supporting 
this view, CHK1 overexpression increases the efficiency of 
transformation by RAS, by suppressing oncogene-induced 
RS [19, 20]. In addition, increased CHEK1 expression and/
or gene copy number gains have been observed in tumors 
with a high degree of genomic instability, which correlated 
with an increased sensitivity to ATR or CHK1 inhibition 
[21, 22]. We therefore reasoned that the presence of high 
CHK1 levels could be used to identify tumor types with 
elevated amounts of RS. 
To explore this possibility, we first interrogated the 
human Cancer Cell Line Enciclopedia (CCLE) dataset for 
CHEK1 mRNA expression (https://portals.broadinstitute.
org/ccle/home) [23]. Supporting our view, CHEK1 levels 
are highest in all kinds of hematopoietic tumors, where 
ATR and CHK1 inhibitors are particularly effective [5, 
6, 22, 24]. After mesothelioma, ES were the solid tumors 
showing the highest levels of CHEK1 mRNA from the 
CCLE dataset. In agreement with this, CHK1 protein 
levels were distinctively higher in a panel of ES lines 
than in primary cells or other osteosarcomas (Figure 1A). 
The presence of high CHK1 levels correlated with an 
increased phosphorylation of histone H2AX (γH2AX) in 
ES cell lines, supporting the presence of RS in these cells. 
Immunohistochemistry (IHC) of ES xenografts confirmed 
the presence of cells positive for γH2AX, which was more 
abundant than on xenografts from other related tumors 
such as neuroblastoma or rhabdomyosarcoma (Figure 
1B). Moreover, γH2AX showed a pan-nuclear distribution, 
which is the pattern that is found in tumors with high 
levels of RS [5] and induced by ATR or CHK1 inhibitors 
[25, 26]. Finally, and to directly evaluate DNA replication 
in ES cells, we analyzed replication fork progression 
on isolated stretched DNA fibers. These experiments 
revealed that fork progression is slower on any ES line 
tested (TC71, A673 and A4573) than in human primary 
retinal pigmentum epithelial (RPE) cells or in U2OS and 
SAOS osteosarcoma cell lines (Figure 1C). Collectively, 
these data reveal the presence of RS in Ewing sarcomas 
Figure 1: Increased rs levels in Ewing sarcomas. A. CHK1 and γH2AX levels evaluated by WB on several ES lines, together with 
2 osteosarcoma lines and 3 human primary cell types. b. γH2AX IHC on mouse xenografts from 3 ES lines (A4573, A673 and TC71), and 
two independent xenografts from ES-related tumors (rhabdomyosarcoma (RMS); neuroblastoma (NB)). Scale bar (black) indicates 20 µm. 
c. Fork rates were measured in stretched DNA fibers prepared from non-ES (RPE, U2OS, SAOS) and ES (TC71, A673 and A4573) cell 
lines. At least 200 tracks were measured per condition. ***P<0.001 by two-tailed t test. 
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suggesting that these tumors could be particularly 
responsive to ATR inhibitors.
To determine the efficacy of ATR inhibitors on 
ES, we first calculated the lethal dose 50 (LD50) of 
these compounds in vitro (Figure 2A). Two independent 
ATR inhibitors (ETP-46464: ATRi hereafter [26] and 
AZ20 [27]) showed higher toxicity for ES cells than 
for human primary cells or non-ES osteosarcomas, and 
significantly lower LD50 values than the PARP inhibitor 
olaparib. Moreover, the toxicity of ATR inhibitors 
correlated with the levels of CHK1 and γH2AX present 
on ES lines (see Figure 1A), consistent with the toxicity 
of these compounds being proportional to the levels of 
RS. Noteworthy, one of the cell lines from our panel was 
Figure 2: sensitivity of Es to Atr inhibitors in vitro. A. LD50 values of 2 independent inhibitors (ETP-46464 [26] and AZ20 [27]) 
and a PARP1 inhibitor (olaparib, PARPi hereafter) on the same lines used in Figure 1B. The LD50 values for temozolomide, currently used 
in ES chemotherapy, were above 100 µM in all lines tested. b. Clonogenic assays illustrating the differential effects of ATRi and PARPi on 
U2OS and A4573 cells. c. DNA content was assessed by flow cytometry on 2 non-ES osteosarcoma lines and 3 ES lines exposed to ATRi 
for 72 hrs (1 µm). D. Western blot illustrating the cleavage of PARP1 on ES lines and U2OS upon a short exposure to ATRi (1 μM, 4 hrs). 
E. FACS analysis of DNA content (PI) and H2AX phosphorylation in U2OS and A4573 cells exposed to ATRi (10 µM, 5 hrs), illustrating 
the increased levels of ATRi-induced RS (as measured by γH2AX in cells with an S-phase DNA content) in ES cells. 
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U2OS, a non-ES osteosarcoma cell line recently identified 
as being highly sensitive to ATR inhibitors due to its 
reliance on the ALT pathway for telomere maintenance 
[28]. The toxicity of ATR inhibitors on all ES lines tested 
was higher (up to 20-fold) than on U2OS. Clonogenic 
assays confirmed a greater impact of ATR inhibition on 
ES cells than on U2OS (Figure 2B). Together, these results 
support that ATR inhibitors are especially toxic for ES 
cells.
Next, we analyzed the effects of ATR inhibition in 
ES cells. First, flow cytometry analyses of DNA content 
confirmed an increased toxicity of ATRi in ES lines, 
at doses at which no obvious impact of the inhibitor 
was observed on the cell cycle distribution of U2OS or 
SAOS-2 osteosarcoma cells (Figure 2C). The compound 
triggered apoptosis in ES cells, evidenced by the 
emergence of cells with a subG1 DNA content, as well 
as by the caspase-mediated cleavage of PARP1 (Figure 
2D). Besides apoptosis, the main mechanism by which 
ATR inhibitors kill cells is by forcing premature mitotic 
Figure 3: Expression of EWsr1 translocations sensitizes cells to Atri. A. WB illustrating the expression of EWS/FLI1 
(measured with a FLI1 antibody) that can be obtained in EWS/FLI1ind MEF upon 4-hydroxy-tamoxifen (OHT)-induced activation of a 
Cre-ERT2 expressed from the ubiquitin promoter (UQ/CreERT2) [41]. OHT was added for 48 hrs at 1 µM. β-ACTIN was used as loading 
control. b. DNA content analyses by flow cytometry illustrating the toxicity of ATRi (5µM, 48 hrs) on WT and EWS/FLI1ind MEF harboring 
UQ-CreERT2 exposed to OHT (1 µM, 48 hrs). SubG1 populations are shaded in red and their percentages are indicated. c. DNA replication 
rates of WT and EWS/FLI1ind MEF harboring UQ-CreERT2 exposed to OHT, as well as of WT MEF infected with a retrovirus expressing the 
MYC oncogene were evaluated by quantifying the incorporation of EdU per nucleus by High Throghput Microscopy. D. WB illustrating 
the expression of EWS/FLI1 (measured with EWS and FLI-1 antibodies) that can be obtained in Flip-In 293T-Rex cells carrying a STAG-
EWS/FLI1 cDNA (EWS/FLI1STAG) upon induction with doxycycline (Dox) (200 ng/ml, 48 hrs). The levels in a clone of Flip-In 293T-Rex 
cells expressing only the STAG peptide are shown as expression controls. CDK2 was used as loading control. E. DNA content analyses by 
flow cytometry illustrating the toxicity of ATRi (1µM, 24 hrs) on EWS/FLI1STAG cells exposed or not to Dox (48 hrs). SubG1 populations are 
shaded in red and their percentages are indicated. F. WB illustrating the expression of EWS/ERG (measured with an EWSR1 antibody) that 
can be obtained in MEF upon infection with a EWS/ERG expressing retrovirus (or empty vector; pBabe). β-ACTIN was used as loading 
control. G. Flow cytometry illustrating the toxicity of ATRi (5µM, 48 hrs) on MEF infected with an EWS/ERG expressing retrovirus (or 
empty vector). SubG1 populations are shaded in red and their percentages are indicated.
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entry in cells suffering from RS [29]. Accordingly, in 
ES cell lines ATR inhibition led to the accumulation of 
cells in the S/G2 phases of the cell cycle. Moreover, flow 
cytometry analyses of H2AX phosphorylation together 
with DNA content revealed that ATR inhibition led to 
increased γH2AX levels specifically in S phase, and 
which were exacerbated in ES (A4573) cells compared 
to U2OS (Figure 2E). Thus, the sensitivity of ES to ATR 
inhibition correlates with an increased induction of RS by 
the compound in these cells.
Next, and to determine whether the sensitivity 
towards ATR inhibitors observed on ES cells was not 
something particular of the chosen cell lines but rather 
a consequence of the initiating oncogenic translocation, 
we first used a mouse transgenic line where EWS/FLI1 
expression can be induced by the Cre recombinase (EWS/
FLI1ind) [30] (Figure 3A). Cre expression was sufficient 
to sensitize EWS/FLI1ind MEFs to ATR inhibition (Figure 
3B). Interestingly, and in contrast to other oncogenes 
that sensitize to limited ATR activity such as MYC [5], 
EWS/FLI expression did not increase DNA replication 
rates as measured by EdU incorporation (Figure 3C). To 
test the effect of EWS/FLI1 expression in human cells 
and independently of Cre we generated a doxycycline-
inducible EWS/FLI1 expressing line in human Flip-
In T-Rex 293T cells (293EWS/FLI1) (Figure 3D). Similar 
to the observations in EWS/FLI1ind MEFs, doxycyclin 
exposure sensitized 293EWS/FLI1 cells to ATRi (Figure 3D, 
,E). In addition to EWS/FLI1, expression of EWS/ERG 
also sensitized cells to ATR inhibition (Figure 3F,G). In 
fact, one of the ATRi-sensitive ES cell lines tested above 
(TTC466) carries an EWS/ERG translocation instead of 
EWS/FLI1. In summary, expression of EWSR1 involving 
translocations sensitizes human and mouse cells to ATR 
inhibitors.
Finally, to determine the efficacy of ATR inhibitors 
in vivo, we evaluated their antitumoral effects using 
xenografts in immunodeficient mice (SCID). Remarkably, 
Figure 4: Efficacy of ATR inhibitors in ES xenografts as single agents. A. Efficacy of AZ20 as monotherapy on the growth 
of ES xenografts (A4573). Treatment started when tumors became palpable. b. Examples of the tumor sizes observed at endpoint from 
A. c. γH2AX IHC on xenografts from A 48 hrs after starting the treatment. Scale bar indicates 30 µm. D. Efficacy of an independent 
ATR inhibitor (MSC253) as monotherapy on the growth of ES xenografts (A4573). Treatment started when tumors became palpable. E. 
Examples of the tumor sizes observed at endpoint from D. F. γH2AX IHC on xenografts from D 48 hrs after starting the treatment. Scale 
bar indicates 30 µm. Error bars indicate s.d. ***P < 0.001.
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oral administration of two independent ATR inhibitors 
reduced the growth of xenografts from A4573 ES cells 
(Figure 4). Moreover, xenografts from mice treated with 
ATR inhibitors presented a generalized accumulation 
of cells with pan-nuclear γH2AX, consistent with the 
mechanism of action of ATR and CHK1 inhibitors [5, 22] 
(Figure 4C,F). Of note, and whereas all current clinical 
trials using ATR inhibitors rely on combination therapies 
with additional genotoxic agents (https://clinicaltrials.
gov/), both ATR inhibitors were used as single agents in 
these experiments. 
DIscUssION
Metastatic Ewing sarcoma is a pediatric tumor of 
very poor prognosis, due to the lack of efficient therapies. 
Current treatments involve genotoxic agents such as 
temozolomide or irinotecan, whose mechanism of action 
involves the generation of RS. In what regards to new 
alternatives, ES cells were also reportedly sensitive to 
PARP inhibitors [23, 31]. However, initial clinical trials 
failed to see a response to these compounds in ES patients 
[32], and thus new therapies are still needed. We here 
provide evidence of a distinctively high sensitivity of 
Ewing sarcomas to ATR inhibitors, which correlates with 
high levels of endogenous RS in these tumors. Both ATR 
inhibitors were significantly more toxic than the PARP 
inhibitor olaparib in all ES lines tested. In addition, all ES 
cell lines were more sensitive to ATR inhibition than the 
ALT-positive cell line U2OS, recently reported as highly 
sensitive to these agents [28]. 
Our discovery of high endogenous levels of RS 
in ES cells also helps to explain the intrinsic sensitivity 
of ES to agents that perturb DNA replication. As 
observed in other tumors suffering from RS, such as 
recombination-deficient ovarian cancers [21] or MYCN-
driven neuroblastomas [33], ES cells present high levels 
of CHK1 expression, which helps them deal with the 
presence of RS. As a consequence, these tumors become 
addicted to a proficient ATR/CHK1 pathway for their 
survival, explaining the high sensitivity of ES cells to 
ATR inhibition. At this point, we do not know why the 
expression of EWSR1 translocation products drives RS in 
ES cells, yet since EWS/FLI1 is a transforming oncogene 
[9] it could simply be another case of oncogene-induced 
RS. However, and in contrast to other oncogenes such as 
MYC or RAS, EWS/FLI1 expression does not increase 
DNA replication, so that a novel mechanism must be 
in place to explain this synthetic lethal interaction. One 
interesting possibility is that the expression of EWSR1 
fusions could perturb the function of endogenous EWSR1, 
which could be the source of RS and genomic instability 
of these tumors. Consistently, a recent report revealed 
a critical role of EWSR1 in facilitating the recruitment 
of DNA repair factors to sites of DNA damage [34]. 
In addition, previous work revealed that depletion of 
EWSR1 reduced the levels of several DNA damage 
response factors, due to alterations in alternative splicing 
[35]. Finally, and as mentioned before, the phenotypes 
of EWSR1-deficient mice are reminiscent of those found 
in ATR mutant mice [13-15]. Hence, it is possible that 
EWSR1 translocations could exert a dominant negative 
function over endogenous EWSR1, leading to RS and 
genomic instability in Ewing sarcomas. Regardless of how 
EWSR1 fusions generate RS, our work provides a basis 
to understand the sensitivity of ES to RS-inducing agents, 
and identifies ATR inhibitors as a potential therapy for ES.
MAtErIALs AND MEtHODs
cell culture
All human cell lines used in this study were cultured 
in RPMI (EuroClone) supplemented with 10% FBS 
(Lonza). Non-ES lines were acquired from ATCC. All ES 
lines were kindly provided by Dr. Enrique de Alava (IBiS, 
Spain). MEF from E13.5 d.p.c. embryos were generated 
by standard methods and grown in DMEM supplemented 
with 15% FBS and under normoxic conditions to minimize 
exposure to reactive oxygen species. For all experiments, 
MEF were used at a low passage (<3). For clonogenic 
assays, 500 cells were seeded per well on six-well plates 
and drugs were added 24 hr later. After 10 days, cells were 
fixed and stained with methylene blue at 0.33% (w/v) in 
methanol, subsequently washed in water and air-dried. For 
the calculation of LD50 values an II-XTT Cell Viability 
assay (Roche) was used. 
Xenografts
8-10 week-old CB17/lcr-Prkdc scid/Crl male mice 
were used. One million A4573 cells were inoculated 
subcutaneously in the right flank of mice. Growing tumor 
masses were measured with the aid of a Vernier caliper, 
and tumor volumes were calculated using the formula: 
(width x (length)2)/2. When tumor volumes reached about 
100 mm3, mice were randomized into two equal groups 
and treatment started. 7 mice were used per treatment 
group. ATR inhibitors or vehicle were administered 
via oral gavage 5 times per week at a dose of 50 mg/
Kg. MSC253 (kind gift from Merck KGaA, Darmstadt, 
Germany) was dissolved in 10%NMP (443778; Sigma-
Aldrich), 50% PEG-300 (202371; Sigma-Aldrich) and 
40% H2O. AZ20 has been previously described [27] and 
was dissolved in 10%NMP and 90% PEG-300. All mouse 
work was performed in accordance with the Guidelines 
for Humane Endpoints for Animals Used in Biomedical 
Research, and under the supervision of the Ethics 




For protein extracts, cells were washed once with 
PBS, and lysed in RIPA buffer (Tris-HCl 50 mM, pH 
7.4, NP-40 1%, Na-deoxycholate 0.25%, NaCl: 150 
mM, EDTA 1 mM) containing protease and phosphatase 
inhibitors (Sigma) or in a buffer containing 50 mM Tris 
(pH 7.5), 8 M urea, and 1% 3-[(3-cholamidopropyl)-
dimethylammonio]-1-propanesulfonate (CHAPS). 
Samples were resolved by SDS-PAGE and analyzed 
by standard Western blotting techniques. For 
immunofluorescence, cells were fixed with 4% PFA and 
permeabilized with 0.1% Triton-X100. Antibodies against 
EWSR1 (sc-6533 and sc-28327, Santa Cruz), FLI1 (sc-
356, Santa Cruz), CHK1 (NCL, Novocastra), PARP1 
(9542S, Cell Signaling), γH2AX (05-636, Millipore), 
β-ACTIN (A5316, Sigma) and CDK2 (sc-163, Santa 
Cruz) were used. Protein blot analyses were performed on 
the LICOR platform (Biosciences).
Inmunohistochemistry
Tissues were fixed in formalin and embedded in 
paraffin for subsequent processing. 2.5-μM sections were 
treated with citrate for antigenic recovery and processed 
for immunohistochemistry with γH2AX (05-636, 
Millipore) antibody. Slides were scanned and digitalized 
with a MIRAX system (Zeiss) for further analysis. 
Flow cytometry
To measure viability, cells were collected, washed 
once with PBS, stained in a DAPI solution (0.2 μg/mL 
DAPI in PBS) and analysed by flow cytometry in a FACS 
Canto II (Becton-Dickinson) machine. For cell cycle 
profiles, cells were collected, washed with PBS and fixed 
in suspension in ice-cold 70% (v/v) ethanol in PBS. After 
washing in PBS, cells were stained in a PBS solution 
containing propidium iodide (10 μg/ml) and RNase A (0.5 
mg/ml) and collected in a Becton-Dickinson FACS Calibur 
machine. For DNA content and γH2AX analysis, p-Ser139 
H2AX (Millipore) antibodies were used as previously 
described [29]. Data was analyzed by using FACS Diva 
(BD Biosciences) and FlowJo (Treestar) softwares. 
DNA fiber analyses Cells were pulse-labeled with 
50 μM CldU (20 min) followed by 250 μM IdU (20 min). 
Labeled cells were collected and DNA fibers were spread 
in buffer containing 0.5% SDS, 200 mM Tris pH 7.4 and 
50 mM EDTA. For immunodetection of labeled tracks, 
fibers were incubated with primary antibodies (for CldU, 
rat anti-BrdU; for IdU, mouse anti-BrdU) for 1 hour at 
room temperature and developed with the corresponding 
secondary antibodies for 30 minutes at room temperature. 
Mouse anti-ssDNA antibody was used to assess fiber 
integrity. Slides were examined with a Leica DM6000 B 
microscope, as described previously [36]. The conversion 
factor used was 1 μm=2.59 kb [37]. 
statistical analyses
Data were represented using Prism 5.0 (GraphPad 
Software), which was also used for statistical analyses. 
One on one comparisons of normal distributions were 
performed using unpaired t-tests. Xenograft growths 
with the different inhibitors were compared with two-
way ANOVAs. In several panels all the datapoints 
per condition are provided. Alternatively, bar graphs 
illustrating the mean ± s.d. are provided. 
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